UBS AM
OBIO icon

UBS AM’s Orchestra BioMed OBIO Stock Holding History

UBS AM’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77M Buy
+642,154
New +$2.63M ﹤0.01% 1915

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS AM's OBIO Position: Q2 2026 in Review

UBS AM opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 642,154 shares worth $2.77M. The stake represents ﹤0.01% of the portfolio and ranks #1915 among its holdings.

72 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • UBS AM held 642,154 shares of Orchestra BioMed worth $2.77M as of Q2 2026.
  • Orchestra BioMed was a new UBS AM position in Q2 2026.
  • Orchestra BioMed made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1915 holding.
  • 72 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.